Kari Kendra
Experienced in Brain Tumor

Dr. Kari Kendra

Hematology | Oncology
Osu Internal Medicine LLC
410 W 10th Ave, 
Columbus, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Brain Tumor
Osu Internal Medicine LLC
410 W 10th Ave, 
Columbus, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kari Kendra is a Hematologist and an Oncologist in Columbus, Ohio. Dr. Kendra is rated as an Experienced provider by MediFind in the treatment of Brain Tumor. Her top areas of expertise are Melanoma, Teratocarcinosarcoma, Olfactory Neuroblastoma, and Merkel Cell Carcinoma.

Her clinical research consists of co-authoring 82 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Brain Tumor.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Ohio State University State Health System
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

OSU INTERNAL MEDICINE LLC
410 W 10th Ave, Columbus, OH 43210
Other Locations
OSU INTERNAL MEDICINE LLC
3900 Stoneridge Ln, Dublin, OH 43017
OSU INTERNAL MEDICINE LLC
2050 Kenny Rd, Columbus, OH 43221

Additional Areas of Focus

Dr. Kendra has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study
Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib
Study Phase: Phase 4
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Biological, Other, Drug
Study Drugs: Dabrafenib, Navitoclax, Trametinib
Study Phase: Phase 1/Phase 2
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Biological
Study Drugs: Pembrolizumab, Talimogene Laherparepvec
Study Phase: Phase 2
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 1 Expansion Cohort Evaluating the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Unresectable Melanoma
A Phase 1 Expansion Cohort Evaluating the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Unresectable Melanoma
Enrollment Status: Completed
Publish Date: April 04, 2023
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 1
View 10 Less Clinical Trials

82 Total Publications

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors.
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors.
Journal: Cancer investigation
Published: October 10, 2025
Similar Doctors
Advanced in Brain Tumor
Dr. Michael A. Caligiuri
Hematology | Oncology
Advanced in Brain Tumor
Dr. Michael A. Caligiuri
Hematology | Oncology
300 W 10th Ave, 
Columbus, OH 
 (0.2 miles away)
614-293-8619
Languages Spoken:
English
See accepted insurances

Michael Caligiuri is a Hematologist and an Oncologist in Columbus, Ohio. Dr. Caligiuri is rated as a Distinguished provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Cutaneous T-Cell Lymphoma (CTCL), and T-Cell Lymphoma.

Advanced in Brain Tumor
Dr. James A. Schmotzer
Hematology Oncology | Hematology | Oncology
Advanced in Brain Tumor
Dr. James A. Schmotzer
Hematology Oncology | Hematology | Oncology

Kettering Independent Medical Group Inc

3535 Pentagon Blvd, Suite 220, 
Beavercreek, OH 
 (57.4 miles away)
937-429-7350
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Schmotzer is a Hematologist Oncology specialist and a Hematologist in Beavercreek, Ohio. Dr. Schmotzer is rated as an Advanced provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Thrombotic Thrombocytopenic Purpura, Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Thrombocytopenia, and Bone Marrow Aspiration. Dr. Schmotzer is currently accepting new patients.

Experienced in Brain Tumor
Dr. Ewa E. Mrozek
Oncology | Hematology
Experienced in Brain Tumor
Dr. Ewa E. Mrozek
Oncology | Hematology

Osu Internal Medicine LLC

2050 Kenny Rd, 
Columbus, OH 
 (0.9 miles away)
614-293-3890
Languages Spoken:
English, Polish, Russian
See accepted insurances
Accepting New Patients

Ewa Mrozek is an Oncologist and a Hematologist in Columbus, Ohio. Dr. Mrozek is rated as a Distinguished provider by MediFind in the treatment of Brain Tumor. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Paget Disease of the Breast, and Inflammatory Breast Cancer. Dr. Mrozek is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kendra's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile